
Contents

<i>Preface</i>	v
<i>List of Contributors</i>	xix
Chapter 1 Standards of Medical Care in Diabetes — 2009 <i>American Diabetes Association</i>	1
1.1. Classification and Diagnosis	1
1.1.1. Classification	1
1.1.2. Diagnosis of Diabetes	2
1.1.3. Diagnosis of Prediabetes	3
1.2. Testing for Prediabetes and Diabetes in Asymptomatic Patients	3
1.2.1. Testing for Prediabetes and Type 2 Diabetes in Adults	4
1.2.2. Testing for Type 2 Diabetes in Children	5
1.2.3. Screening for Type 1 Diabetes	5
1.3. Detection and Diagnosis of GDM	5
1.4. Prevention/Delay of Type 2 Diabetes	7
1.5. Diabetes Care	9
1.5.1. Initial Evaluation	9
1.5.2. Management	9
1.5.3. Glycemic Control	9
1.5.3.1. Assessment of glycemic control	9
1.5.3.2. Glycemic goals in adults	13
1.6. Prevention and Management of Diabetes Complications	18
1.6.1. CVD	18
1.6.1.1. Hypertension/blood pressure control	18
1.6.1.2. Dyslipidemia/lipid management	21
1.6.1.3. Antiplatelet agents	24
1.6.1.4. Smoking cessation	25
1.6.2. Retinopathy Screening and Treatment	25
References	27

Chapter 2	Clinical Presentation of Retinopathy	37
	<i>José Cunha-Vaz</i>	
2.1.	Preclinical Stage	38
2.2.	Nonproliferative Diabetic Retinopathy	40
2.3.	Complications of Diabetic Retinal Disease	42
	2.3.1. Diabetic Macular Edema	42
	2.3.2. Preproliferative and Proliferative Diabetic Retinopathy	46
	References	49
Chapter 3	Clinical Diagnostic Methodologies	51
3.1.	Fundus Photography and Fluorescein Angiography	51
	<i>Lilianne Duarte and José Cunha-Vaz</i>	
	3.1.1. Mild Nonproliferative Retinopathy	54
	3.1.2. Moderate Nonproliferative Retinopathy Without Macular Edema	55
	3.1.3. Nonproliferative Retinopathy with Clinically Significant Macular Edema	55
	3.1.4. Severe Nonproliferative Retinopathy	56
	3.1.5. Diabetic Retinopathy Screening	56
	3.1.6. Grading Diabetic Retinopathy from Stereoscopic Color Fundus Photographs-an Extension of the Modified Airlie House Classification. ETDRS Report Number 10	57
	References	60
3.2.	Measurements of Retinal Thickness	61
	<i>João Figueira, Rui Bernardes and José Cunha-Vaz</i>	
	3.2.1. Retinal Thickness Analyzer (RTA)	62
	3.2.2. Optical Coherence Tomography (OCT)	62
	3.2.3. Retinal Thickness Measurements	63
	3.2.4. Macular Edema	65
	References	68
3.3.	Vitreous Fluorometry and Retinal Leakage Measurements	69
	<i>José Cunha-Vaz and Conceição Lobo</i>	
	3.3.1. Basic Principles of Ocular Fluorometry	70
	3.3.1.1. Quantitative Measurement of Fluorescein	70
	3.3.1.2. Instrumentation and Measurement	71
	3.3.1.3. Evaluation of Blood-retinal Barrier Permeability	71
	3.3.2. Retinal Leakage Analyzer	72
	3.3.3. Experimental Studies	73
	3.3.4. Clinical Studies	74
	3.3.5. Prognostic Value of Leakage Measurements	75
	References	76
3.4.	Blood Flow	77
	<i>José Cunha-Vaz</i>	
	3.4.1. General Hemodynamic Principles	77

	3.4.2. Pressure-Volume Relationships	78
	3.4.3. Retinal Blood Volume	78
	3.4.4. Pressure-Flow Relationships	78
	3.4.5. Biophysical Factors Affecting Retinal Capillary Flow	78
	3.4.6. Velocity and Intermittence of Retinal Capillary Flow	79
	3.4.7. Regulation of Retinal Capillary Blood Flow	79
	3.4.8. Autoregulation of Retinal Blood Flow	80
	3.4.9. Measurement of Blood Flow	81
	3.4.10. Retinal Blood Flow in Diabetes	81
	References	82
	3.5. Retinal Neural Impairment	83
	<i>Miguel Castelo-Branco</i>	
	3.5.1. New Psychophysical Techniques to Assess Retinal Neural Impairment in Diabetic Retinopathy	84
	3.5.2. Classical Electrophysiological Findings in Diabetic Retinopathy	86
	3.5.3. Oscillatory Potentials (OPs)	90
	3.5.4. Pattern ERG	91
	3.5.5. Multifocal Electrophysiology	91
	3.5.6. Future Directions	92
	References	93
	Abbreviations	95
	3.6. Multimodal Macula Mapping	95
	<i>Rui Bernardes, Conceição Lobo and José Cunha-Vaz</i>	
	3.6.1. Imaging Systems	96
	3.6.2. Multimodal Macula Mapping. Integration of Information and Representation	96
	3.6.3. Multimodal Macula Mapping	96
	3.6.4. Contribution to the Evaluation of Diabetic Retinopathy	98
	References	100
Chapter 4	Pathogenesis	101
	4.1. Molecular Mechanisms	101
	<i>Paulo Pereira</i>	
	4.1.1. Glucose Transport in the Retina	102
	4.1.2. Aldose Reductase and Polyol Pathway	105
	4.1.3. Protein Glycation	106
	4.1.4. VEGF and Angiogenesis	107
	4.1.5. Activation of Protein Kinase C	109
	4.1.6. Oxidative Stress	111
	4.1.7. Hyperglycemia and Oxidative Damage: A Unifying Hypothesis	112
	4.1.8. Hyperglycemia and Production of Superoxide	113
	4.1.9. Activation of Hexosamine Pathway	114
	4.1.10. Activation of PKC	115

4.1.11.	Formation of AGEs	115
4.1.12.	Production of Nitric Oxide	115
4.1.13.	Animal Models	116
4.1.14.	Genetic Factors	116
References		117
4.2.	Cell Factors	125
	<i>António Francisco Ambrósio</i>	
4.2.1.	Cell Changes Relevant to Blood-Retinal Barrier Breakdown	126
4.2.2.	Tight Junctions	126
4.2.3.	Alterations in Tight Junctions Expression and Phosphorylation	126
4.2.4.	Microvascular Cell Death	128
4.2.5.	Neuronal Dysfunction and Death	129
4.2.6.	Glial Cells Reactivity and Changes	131
4.2.7.	Glutamate Excitotoxicity in Diabetic Retinopathy: Involvement of Neurons and Glial Cells	132
4.2.8.	Microglia	134
4.2.9.	The Outsiders: Leukocytes and Platelets	134
4.2.10.	Low-Grade Chronic Inflammation	134
4.2.11.	Microthrombosis	136
4.2.12.	Concluding Remarks	136
References		137
4.3.	Neovascularization in Diabetic Retinopathy	143
	<i>Ermelindo Leal and António Francisco Ambrósio</i>	
4.3.1.	Ischemia and Neovascularization in Diabetic Retinopathy	143
4.3.2.	Growth Factors	143
4.3.3.	Basic Fibroblast Growth Factor (bFGF)	144
4.3.4.	Insulin-Like Growth Factors (IGF)	144
4.3.5.	Platelet-Derived Growth Factor (PDGF)	145
4.3.6.	Vascular Endothelial Growth Factor (VEGF)	146
4.3.7.	Conclusions	147
References		148
4.4.	Candidate Genes of Diabetic Retinopathy	152
	<i>Alda Ambrósio</i>	
4.4.1.	Molecular Genetics Approaches to Gene Mapping in Complex Human Disease	152
4.4.2.	Genetic Susceptibility in Diabetic Retinopathy	153
4.4.3.	Candidate Genes in Diabetic Retinopathy	154
4.4.4.	Aldose Reductase Gene	155
4.4.5.	VEGF Gene	155
4.4.6.	RAGE Gene	156
4.4.7.	Angiotensin-Converting Enzyme Gene	156
4.4.8.	PAI-1 Gene	157
4.4.9.	Endothelin Genes	157

	4.4.10. Nitric Oxide Synthase Genes	158
	4.4.11. Other Candidate Genes	158
	4.4.12. Concluding Remarks	158
	References	159
Chapter 5	Epidemiology	165
	<i>José Rui Faria Abreu</i>	
	5.1. Prevalence of Visual Impairment	165
	5.1.1. Prevalence of Visual Impairment in Diabetic Patients	168
	5.1.2. Prevalence of Blindness in Diabetic Patients	168
	5.2. Incidence of Visual Impairment	169
	5.2.1. Visual Impairment	170
	5.2.1.1. Type 1 diabetes	170
	5.2.1.2. Type 2 diabetes	171
	5.2.2. Blindness	171
	5.2.2.1. Type 1 diabetes	171
	5.2.2.2. Type 2 diabetes	171
	5.3. Risk Factors for Visual Loss	172
	5.3.1. Sex	172
	5.3.2. Race	172
	5.3.3. Age	172
	5.3.4. Duration of Diabetes	172
	5.3.5. Severity of Retinopathy	172
	5.3.6. Macular Edema	173
	5.3.7. Metabolic Control	173
	5.3.8. Hypertension	174
	5.3.9. Nephropathy	174
	5.4. Economic Costs of Visual Impairment and Blindness	174
	5.5. Prevalence of Retinopathy	175
	5.5.1. Type 1 Diabetes	175
	5.5.2. Type 2 Diabetes	175
	5.6. Risk Factors of Retinopathy	177
	5.6.1. Type 1 Diabetes	177
	5.6.1.1. Duration of diabetes	177
	5.6.1.2. Age at diagnosis	178
	5.6.1.3. Glycemic control	178
	5.6.1.4. Blood pressure control	179
	5.6.1.5. Pregnancy	179
	5.6.1.6. Height, weight and body mass index (BMI)	180
	5.6.1.7. Serum lipid levels	180
	5.6.1.8. Proteinuria	180
	5.6.1.9. Cigarette smoking	180
	5.6.1.10. Alcohol	181
	5.6.1.11. Physical activity	181
	5.6.1.12. Myopia	181

5.6.2.	Type 2 Diabetes	181
5.6.2.1.	Duration of diabetes	181
5.6.2.2.	Age at examination	181
5.6.2.3.	Treatment	182
5.6.2.4.	Glycemic control	182
5.6.2.5.	Blood pressure	183
5.6.2.6.	Cholesterol and triglycerides	183
5.6.2.7.	Renal involvement	183
5.6.2.8.	Body mass index (BMI)	183
5.6.2.9.	Cigarette smoking and alcohol	184
5.6.2.10.	Physical activity	184
5.6.2.11.	Cataract extraction	184
5.7.	Retinopathy, Comorbidity and Mortality	184
5.7.1.	Comorbidity	184
5.7.2.	Mortality	185
5.8.	Health Care Delivery	185
5.8.1.	Economy	187
5.8.1.1.	Identification of costs of screening and treatment	187
5.8.1.2.	Quality of life	188
5.8.1.3.	Health care economic analyses	189
5.8.1.4.	Cost-effectiveness in diabetic retinopathy	189
	References	190
Chapter 6	Major Clinical Trials on Treatment for Diabetic Retinopathy	201
	<i>Luisa Ribeiro</i>	
	Clinical Trials	201
6.1.	Photocoagulation	202
6.1.1.	Diabetic Retinopathy Study (DRS)	202
6.1.2.	Early Treatment Diabetic Retinopathy Study (ETDRS)	203
6.2.	Vitrectomy	204
6.2.1.	Diabetic Retinopathy Vitrectomy Study (DRVS)	205
6.3.	Medical Approaches	206
6.3.1	Diabetes Control and Complications Trial (DCCT)	206
6.3.2	United Kingdom Prospective Diabetes Study (UKPDS)	207
	References	207
Chapter 7	Photocoagulation for Macular Edema and Proliferative Retinopathy	211
	<i>Francisco Gómez-Ulla</i>	
7.1.	Rationale and Results of Photocoagulation	211
7.1.1.	Diabetic Macular Edema: Results	213
7.1.2.	Proliferative Diabetic Retinopathy: Results	214
7.2.	Clinical Evaluation and Pre-treatment Options	214

	7.2.1. Macular Edema	214
	7.2.2. Proliferative Diabetic Retinopathy	217
7.3.	Laser Treatment Techniques	218
	7.3.1. Macular Edema	218
	7.3.2. Proliferative Retinopathy	222
7.4.	Post-operative Follow-up and Complications	224
	7.4.1. Macular Edema	224
	7.4.2. Proliferative Retinopathy	225
7.5.	Special Cases	227
	7.5.1. Proliferative Retinopathy and Macular Edema	227
	7.5.2. Macular Edema and Traction	228
	7.5.3. Diabetic Retinopathy and Cataract Surgery	228
	7.5.4. Proliferative Retinopathy and Traction on Vitreous Hemorrhage	229
7.6.	Conclusions and General Guidelines	230
	References	231
Chapter 8	Vitrectomy for Diabetic Retinopathy	237
	<i>José Carlos Pastor</i>	
8.1.	Surgical Indications	237
	8.1.1. Clearing Media Opacities	237
	8.1.1.1. Non-clearing vitreous hemorrhage	237
	8.1.1.2. Dense premacular hemorrhages	238
	8.1.1.3. Dense asteroid hyalosis	238
	8.1.2. Tractional Complications	238
	8.1.2.1. Tractional retinal detachment and tractional macular detachment	239
	8.1.2.2. Combined tractional and rhegmatogenous retinal detachment	240
	8.1.2.3. Severe equatorial fibrovascular proliferation	240
	8.1.2.4. Anterior hyaloidal fibrovascular proliferation	240
	8.1.3. Other Indications	241
	8.1.3.1. Severe neovascular proliferation	241
	8.1.3.2. Red blood cell-induced glaucomas	241
	8.1.3.3. Macular edema	241
	8.1.3.4. Complications of previous vitrectomies	242
8.2.	Managing Vitrectomy-Associated Cataracts	243
8.3.	Surgical Objectives and Techniques	244
	8.3.1. Media Opacities	244
	8.3.2. Vitreoretinal Traction	244
	8.3.2.1. Techniques	244
	8.3.3. Control of Hemorrhage and Vascular Proliferation	245
	8.3.3.1. Hemorrhage	245
	8.3.3.2. Vascular Proliferation	246

8.4.	Outcomes and Complications of Vitrectomy in Diabetic Retinopathy	246
8.4.1.	Outcomes	246
8.4.2.	Complications	247
8.4.2.1.	Recurrent vitreous hemorrhage	247
8.4.2.2.	Retinal breaks	248
8.4.2.3.	Retinal detachment	248
8.4.2.4.	Iris rubeosis and neovascular glaucoma	248
8.4.2.5.	Corneal epithelial complications	249
8.4.2.6.	Fibrin formation	249
8.5.	New Instrumentation	249
8.6.	Conclusions	251
	References	251
Chapter 9	Medical Management of Diabetic Retinopathy	257
	<i>José Rui Faria Abreu and José Cunha-Vaz</i>	
9.1.	Glycemic Control	257
9.1.1.	Glycemic Control and Diabetic Retinopathy	258
9.1.1.1.	Type 1 diabetes	258
9.1.1.2.	Type 2 Diabetes	259
9.2.	Blood Pressure Control	259
9.2.1.	Type 1 Diabetes	259
9.2.2.	Type 2 Diabetes	260
9.3.	Dyslipidemic Control	260
9.4.	Treatment of Anemia	261
9.5.	Experimental Therapies	262
9.5.1.	Modulation of Antithrombotic Function of the Endothelium: Platelet Function Inhibitors	262
9.5.2.	Angiotensin-Converting Enzyme Inhibitors	263
9.5.3.	Inhibitors of the Inducible Form of Nitric Oxide Synthase	263
9.5.4.	Antioxidants	264
9.5.5.	Inhibitors of Protein Kinase C (PKC)	265
9.5.6.	Inhibition of Nonenzymatic Glycation of Proteins and Advanced Glycation End Products	265
9.5.6.1.	Aminoguanidine	266
9.5.6.2.	Amadorins	266
9.5.6.3.	Pyridoxal phosphate	266
9.5.7.	Aldose Reductase Inhibitors	266
9.5.8.	Rheological Agents	267
9.5.9.	Antiinflammatory Agents	267
9.5.10.	Angiogenesis Signaling Inhibitors	268
9.5.10.1.	VEGF	269
9.5.10.2.	Pigment-epithelium derived factor	269
9.5.10.3.	Growth hormone	270

9.6.	Conclusions	270
	References	270
Chapter 10	An Integrated Perspective on Diabetic Retinopathy in Type 2 Diabetes <i>José Cunha-Vaz</i>	279
10.1.	Limitations of Present Classifications of Nonproliferative Diabetic Retinopathy	280
10.2.	Natural History of the Initial Stages of NPDR	281
10.3.	Markers of Diabetic Retinal Disease	283
10.3.1.	Microaneurysms/Hemorrhages. Red-dots Formation and Disappearance Rates	283
10.3.2.	Alteration of the BRB. Fluorescein Leakage Measurements	286
10.3.3.	Macular Edema. Retinal Thickness Measurements	289
10.3.4.	Retinal Blood Flow and Capillary Closure	292
10.3.5.	Neuronal and Glial Cells Changes	294
10.3.6.	Multimodal Imaging of the Retina	295
10.4.	Characterization of Retinopathy Phenotypes	296
10.4.1.	Follow-up Studies of the Initial Stages of Diabetic Retinopathy by Multimodal Retinal Imaging	296
10.4.2.	Progression of Nonproliferative Retinopathy Under Stabilized Metabolic Control	300
10.5.	Dominant Pathophysiological Mechanisms of Disease Progression	301
10.5.1.	Aging Phenomena	301
10.5.2.	Hemodynamic Phenomena	302
10.5.3.	Thrombotic Phenomena	303
10.5.4.	Adjuvant Phenomena	304
10.6.	Biochemical Pathways Involved	304
10.7.	Candidate Phenotype/Genotype Correlations	305
10.8.	Relevance for Clinical Trial Design	308
10.9.	Relevance for Clinical Management	309
10.10.	Targeted Treatments	310
10.11.	Determining Risk in the Individual Patient. Preventative Ophthalmology	311
	References	313
	<i>Index</i>	319